Your browser doesn't support javascript.
loading
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
Ali, Moiez; Kaltenbrun, Erin; Anderson, Gray R; Stephens, Sarah Jo; Arena, Sabrina; Bardelli, Alberto; Counter, Christopher M; Wood, Kris C.
Affiliation
  • Ali M; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Kaltenbrun E; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Anderson GR; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Stephens SJ; Department of Pharmacology and Cancer Biology, Duke University, Durham, North California 27710, USA.
  • Arena S; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
  • Bardelli A; Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Torino, Italy.
  • Counter CM; Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
  • Wood KC; Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Torino, Italy.
Nat Commun ; 8: 15617, 2017 06 08.
Article in En | MEDLINE | ID: mdl-28593995

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Proto-Oncogene Proteins p21(ras) / Drug Resistance, Neoplasm / Cetuximab / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2017 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Proto-Oncogene Proteins p21(ras) / Drug Resistance, Neoplasm / Cetuximab / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2017 Type: Article Affiliation country: United States